Clearmind Medicine Inc. (NASDAQ: CMND) stock fell -1.62% on Monday to $0.18 against a previous-day closing price of $0.18. With 1.33 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.37 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.1900 whereas the lowest price it dropped to was $0.1700. The 52-week range on CMND shows that it touched its highest point at $9.00 and its lowest point at $0.17 during that stretch. Beta for the stock currently stands at -2.35.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CMND was down-trending over the past week, with a drop of -56.50%, but this was down by -55.86% over a month. Three-month performance dropped to -67.26% while six-month performance fell -95.03%. The stock lost -97.97% in the past year, while it has lost -94.41% so far this year.
Float and Shares Shorts:
At present, 7.09 million CMND shares are outstanding with a float of 6.53 million shares on hand for trading. On Aug 30, 2023, short shares totaled 0.19 million, which was 2.73% higher than short shares on Jul 30, 2023. In addition to Dr. Adi Zuloff-Shani Ph.D. as the firm’s Chief Exec. Officer, Mr. Alan Mark Rootenberg B.Com., B.Comm, C.A., CPA serves as its Chief Financial Officer.
Institutional Ownership:
Through their ownership of 3.14% of CMND’s outstanding shares, institutional investors have minority control over the company. Other institutions hold — of CMND, in contrast to — held by mutual funds. Shares owned by individuals account for –. With a 2.21% stake in CMND, the AdvisorShares Psychedelics ETF is the largest stakeholder. A total of 123,257 shares are owned by the mutual fund manager. The Fidelity Nasdaq Composite Index E, which owns about 0.93% of CMND stock, is the second-largest Mutual Fund holder. It holds 51,955 shares valued at 20314.0.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CMND since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.
Summary of Insider Activity:
Insiders traded CMND stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has remained unchanged to 0 while that of sell transactions has risen to 1 over the past year. The total number of shares bought during that period was 0 while 64,444 shares were sold.
